8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General

High Frequency Electromagnetic Radiation Stimulates Neuronal Growth and Hippocampal Synaptic Transmission

Bioeffects Seen

Ma S, Li Z, Gong S, Lu C, Li X, Li Y · 2023

Share:

The findings suggest that 0.138 THz waves may have potential as a neuromodulation technique for enhancing neuronal structure and synaptic function rather than causing neuronal damage.

Plain English Summary

Summary written for general audiences

This study examined the effects of 0.138 terahertz (THz) radiation on neuronal growth and synaptic transmission in hippocampal tissue. The researchers found that cumulative THz radiation promoted neuronal cytosol growth, increased dendritic spine density, and improved synaptic transmission efficiency in the CA1 region, with effects persisting for over 10 minutes after exposure ended.

Why This Matters

Terahertz radiation occupies a unique position in the electromagnetic spectrum between microwave and infrared frequencies, with wavelengths that can interact with the rotation and vibration modes of biomolecules. This study's investigation of potential beneficial neuromodulatory effects represents a different research direction from typical EMF health effects studies focused on safety thresholds and potential harms.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Ma S, Li Z, Gong S, Lu C, Li X, Li Y (2023). High Frequency Electromagnetic Radiation Stimulates Neuronal Growth and Hippocampal Synaptic Transmission.
Show BibTeX
@article{ma_s_li_z_gong_s_lu_c_li_x_li_y_ce3358,
  author = {Ma S and Li Z and Gong S and Lu C and Li X and Li Y},
  title = {High Frequency Electromagnetic Radiation Stimulates Neuronal Growth and Hippocampal Synaptic Transmission},
  year = {2023},
  doi = {10.1016/j.jtho.2023.03.015},
  
}
DOI: 10.1016/j.jtho.2023.03.015PubMed: 37190651

Quick Questions About This Study

This appears to be a database classification error. The study examines a pharmaceutical cancer treatment (D-1553/garsorasib) for lung cancer patients, not electromagnetic field exposures or their health effects.
The oral cancer drug achieved a 40.5% objective response rate in 74 evaluable patients with KRAS G12C-mutated lung cancer, with most patients tolerating the treatment well despite some side effects.
Among 79 treated patients, 30 patients (38.0%) experienced grade 3 or 4 adverse events, though researchers reported these were generally manageable and patients tolerated treatment well.
The median progression-free survival was 8.2 months overall, with 7.6 months at the recommended phase 2 dose of 600 mg twice daily in this Chinese patient population.
In patients with brain metastasis, the drug achieved a 17% objective response rate and 100% disease control rate, showing some activity even in this challenging patient population.